Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• KRAS mutations are prevalent in human cancers, correlating with poor prognosis and therapeutic resistance.
• Let-7 microRNAs function as tumor suppressors and are often downregulated in solid tumors with KRAS mutations.

Purpose of the Study:

• To investigate the potential of let-7 as a chemosensitizer in KRAS-mutant cancers.
• To evaluate the efficacy of let-7b repletion in combination with standard chemotherapies.

Main Methods:

• Utilized let-7b mimics for transfection in KRAS-mutant tumor cells.
• Assessed the impact of let-7b on KRAS expression, downstream signaling pathways (MEK/ERK, PI3K/AKT), apoptosis, epithelial-mesenchymal transition, and resistance markers (β-tubulin III, RRM2).
• Tested combination therapy with paclitaxel and gemcitabine.

Main Results:

• Let-7b repletion selectively sensitized KRAS-mutant cells to paclitaxel and gemcitabine.
• Transfected let-7b mimic downregulated mutant KRAS expression.
• Combination therapy inhibited MEK/ERK and PI3K/AKT signaling, induced apoptosis, and reversed epithelial-mesenchymal transition.
• Let-7b repletion reduced expression of β-tubulin III and RRM2, proteins linked to drug resistance.

Conclusions:

• Let-7b acts as a potent chemosensitizer in KRAS-mutant cancer cells.
• Let-7b repletion resensitizes tumors to paclitaxel and gemcitabine by targeting oncogenic pathways and resistance mechanisms.
• Let-7 microRNAs represent a promising new class of chemosensitizers for treating KRAS-mutant tumors.